Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
6 search results for:

Vandetanib 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 08-12-2021 | SABCS 2021 | Conference coverage | Article

    Appropriate framework must guide targeted therapy for metastatic breast cancer

    Targeted therapies included vistusertib (targeting mTOR alterations), AZD4547 ( FGFR ), capivasertib ( AKT ), sapitinib ( HER2 or EGFR ), selumetinib ( MEK ), vandetanib ( VEGF or EGFR ), bicalutamide (androgen receptor), olaparib ( PARP ), and alpelisib ( PIK3CA ).

    Author:
    Laura Cowen
    Published in:
    SABCS 2021; 7–10 December
  2. 25-11-2020 | Tyrosine kinase inhibitors | News | Article

    Bleeding risk doubled during concurrent VEGFR–TKI, anticoagulant therapy

    The patients received one or more VEGFR–TKIs (pazopanib, sunitinib, sorafenib, axitinib, regorafenib, vandetanib, lenvatinib, or cabozantinib) and factor Xa inhibitors (low molecular weight heparin [LMWH] including enoxaparin or the direct oral anticoagulants [DOACs] rivaroxaban or apixaban) between 2010 and 2018 whilst undergoing treatment for a variety of cancers, including renal cell carcinoma (48.8%), sarcoma (23.3%), and colorectal cancer (11.6%).

    Author:
    Laura Cowen
    Published in:
    Cancer 2020; doi:10.1002/cncr.33337
  3. 22-02-2018 | NICE | News | Article
    approvalsWatch

    Cabozantinib, lenvatinib, sorafenib approved for UK thyroid cancer patients

    Of note, the technology appraisal for the multikinase inhibitor vandetanib and its associated recommendations for thyroid cancer will be released at a later date.

  4. 19-09-2017 | Thyroid cancer | Article

    A retrospective review of the multidisciplinary management of medullary thyroid cancer: eligibility for systemic therapy

    This retrospective review by Geller et al. found that localized and regional medullary thyroid cancer treatment patterns reflect multidisciplinary management based on disease characteristics. Geller G, Laskin J, Cheung WY & Ho C. Thyroid Res 2017; 10:6. doi:10.1186/s13044-017-0041-6

  5. 21-07-2016 | Endocrine cancers | Book chapter | Article

    Management of Patients with Metastatic Medullary Thyroid Carcinoma: The Role for Systemic Therapy

    This chapter outlines a suggested approach to the use of systemic therapy in progressive metastatic medullary thyroid cancer. Fareau GG. In: Medullary Thyroid Cancer . Edited by Wang TS & Evans DB. Springer International Publishing, 2016. doi:10.1007/978-3-319-39412-1_15

  6. 10-08-2016 | Head and neck cancers | Article

    The rationale for including immune checkpoint inhibition into multimodal primary treatment concepts of head and neck cancer

    Tinhofer et al. analyze the available evidence for combining immune checkpoint inhibitors with radiotherapy in primary treatment of squamous cell carcinomas of the head and neck. Tinhofer I et al. Cancers Head Neck 2016;1:8. doi:10.1186/s41199-016-0009-6

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.